Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Toshiki Terao, MD, Yoichi Machida, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1861.

https://doi.org/10.1182/blood-2019-130845

Published: 2019

Journal Articles

Clinical Features, Diagnosis, and Prognosis of 22 Cases of Neurolymphomatosis : A Single-Institution Experience over 12 Years

Kentaro Narita, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1630.

https://doi.org/10.1182/blood-2019-126706

Published: 2019

Journal Articles

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Akihiro Kitadate, MD PhD, Kentaro Narita, MD, Kota Fukumoto, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Youichi Machida, MD, Naoto Takahashi, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 2839.

https://doi.org/10.1182/blood-2019-122799

Published: 2019

Journal Articles

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Hiroyuki Takamatsu, MD PhD, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Mikio Ueda, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3083.

https://doi.org/10.1182/blood-2019-122398

Published: 2019

Journal Articles

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Blood (2019) 134 (Supplement_1): 350.

https://doi.org/10.1182/blood-2019-126798

Published: 2019

Journal Articles

Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

Takeshi Yoroidaka, MD, Hiroyuki Takamatsu, MD PhD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Kyoko Yoshihara, MD PhD, Satoshi Yoshihara, MD PhD, Mikio Ueda, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3130.

https://doi.org/10.1182/blood-2019-126552

Published: 2019

Journal Articles

Prognostic Implications of Metabolic Total Volume and Total Lesion Glycolysis Assessed By PET/CT Combined with High Levels of Bone Marrow Plasma Cells Percentages As a Potential Risk Model in Patients with Newly Diagnosed Multiple Myeloma

Toshiki Terao, MD, Yoichi Machida, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3193.

https://doi.org/10.1182/blood-2019-126784

Published: 2019

Journal Articles

Clinical and Prognostic Impact of (11;14)(q13;q32) Translocation on Patients with Multiple Myeloma

Daisuke Miura, MD, Kentaro Narita, MD, Ayumi Kuzume, MD, Rikako Tabata, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 5507.

https://doi.org/10.1182/blood-2019-130809

Published: 2019

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Quantification of Residual Bone Marrow Plasma Cells By Eight-Color Flow Cytometry in Patients with Multiple Myeloma: Comparison between the Dura Clone RE PC Panel (Beckman Coulter) and the Euro Flow MM-MRD Panel (Cytognos)

Kentaro Narita, MD, Takeshi Yoroidaka, MD, Momoko Fujisawa, MD, Hiroyuki Takamatsu, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2018-99-116108

Published: 2018

Journal Articles

Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing

Hiroyuki Takamatsu, MDPhD, Naoki Takezako, MD PhD, Rachel K Wee, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Kosei Matsue, MD PhD, Shinji Nakao, MD PhD

Blood (2018) 132 (Supplement 1): 258.

https://doi.org/10.1182/blood-2018-99-111250

Published: 2018

Journal Articles

Prevalence and Clinical Characteristics of False-Positive Aspergillus Galactomannan Test in Healthy Subjects and Patients with Hematologic Malignancies

Yoshiaki Abe, Kentaro Narita, MD, Hiroki Kobayashi, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 2408.

https://doi.org/10.1182/blood-2018-99-110939

Published: 2018

Journal Articles

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Blood (2018) 132 (Supplement 1): 1960.

https://doi.org/10.1182/blood-2018-99-112155

Published: 2018

Journal Articles

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

Yoshiaki Abe, Yamashita Takeshi, Ueda Mikio, Kazutaka Sunami, MD PhD, Kentaro Narita, MD, Hiroki Kobayashi, MD, Hiroyuki Takamatsu, MD PhD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 4477.

https://doi.org/10.1182/blood-2018-99-109934

Published: 2018

Journal Articles

N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Is Associated with Both Left Ventricular Diastolic Dysfunction and Myeloma-Related Renal Insufficiency and Robustly Predicts Mortality in Patients with Symptomatic Multiple Myeloma

Yoshiaki Abe, Tetsuya Kobayashi, MD, Kentaro Narita, MD, Hiroki Kobayashi, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2018-99-110064

Published: 2018

Journal Articles

Diagnostic Significance of Hyperintense Lesion in the Pons on Brain Magnetic Resonance Imaging in Patients with Intravascular Lymphoma

Yoshiaki Abe, Kentaro Narita, MD, Hiroki Kobayashi, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2018-99-110946

Published: 2018

Journal Articles

Erythropoietin Level and Percentage of Urinary Albumin Are Important for Renal Recovery in Patients with Multiple Myeloma Receiving Novel Agents

Hiroki Kobayashi, MD, Yoshiaki Abe, Daisuke Miura, MD, Kentaro Narita, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 5571.

https://doi.org/10.1182/blood-2018-99-110495

Published: 2018

Journal Articles

Clinical Features and Predictive Factors of Early Mortality in Patients with MM Outside of Clinical Trials

Hiroki Kobayashi, MD, Yoshiaki Abe, Daisuke Miura, MD, Kentaro Narita, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2018-99-113750

Published: 2018

Journal Articles

Prognostic Value of Interim and End-of-Treatment PET-CT in Patients with Mature T-Cell and NK-Cell Lymphomas: A 10-Year Single Institution Study

Akihiro Kitadate, MD PhD, Kota Fukumoto, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, Kentaro Narita, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 2930.

https://doi.org/10.1182/blood-2018-99-113746

Published: 2018

Journal Articles

Prognostic Relevance of Medullary Abnormalities in the Appendicular Skeleton Detected By Positron Emission Tomography-Computed Tomography in Patients with Newly Diagnosed Multiple Myeloma

Yoshiaki Abe, Kentaro Narita, MD, Hiroki Kobayashi, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Toshihiro Ouchi, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2018-99-110062

Published: 2018

NARROW

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Clinical Features, Diagnosis, and Prognosis of 22 Cases of Neurolymphomatosis : A Single-Institution Experience over 12 Years

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

Prognostic Implications of Metabolic Total Volume and Total Lesion Glycolysis Assessed By PET/CT Combined with High Levels of Bone Marrow Plasma Cells Percentages As a Potential Risk Model in Patients with Newly Diagnosed Multiple Myeloma

Clinical and Prognostic Impact of (11;14)(q13;q32) Translocation on Patients with Multiple Myeloma

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Quantification of Residual Bone Marrow Plasma Cells By Eight-Color Flow Cytometry in Patients with Multiple Myeloma: Comparison between the Dura Clone RE PC Panel (Beckman Coulter) and the Euro Flow MM-MRD Panel (Cytognos)

Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing

Prevalence and Clinical Characteristics of False-Positive Aspergillus Galactomannan Test in Healthy Subjects and Patients with Hematologic Malignancies

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Is Associated with Both Left Ventricular Diastolic Dysfunction and Myeloma-Related Renal Insufficiency and Robustly Predicts Mortality in Patients with Symptomatic Multiple Myeloma

Diagnostic Significance of Hyperintense Lesion in the Pons on Brain Magnetic Resonance Imaging in Patients with Intravascular Lymphoma

Erythropoietin Level and Percentage of Urinary Albumin Are Important for Renal Recovery in Patients with Multiple Myeloma Receiving Novel Agents

Clinical Features and Predictive Factors of Early Mortality in Patients with MM Outside of Clinical Trials

Prognostic Value of Interim and End-of-Treatment PET-CT in Patients with Mature T-Cell and NK-Cell Lymphomas: A 10-Year Single Institution Study

Prognostic Relevance of Medullary Abnormalities in the Appendicular Skeleton Detected By Positron Emission Tomography-Computed Tomography in Patients with Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only